Alkermes has reached an agreement to buy Avadel Pharma in a deal valued at up to $2.1 billion, claiming rights to an ...

Onsite at ESMO 2025, pharmaphorum spoke with Adrian Jubb, head of oncology and neurology clinical development at Corcept, and ...

Takeda has partnered with China's Innovent Biologics for a pair of late-stage cancer therapies, in a deal that includes an ...

An oversubscribed seed funding round will give Procyon the financial resources it needs to launch its first diagnostic – ...

Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ...

The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher ...

The company ended the first half of this year with €3.1 billion ($3.6 billion) in cash reserves, and is due to report its ...

Merck KGaA has become the third pharma company to reach an agreement with the Trump administration to cut the cost of some of ...

However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) came out of the blocks strongly at the ESMO congress with ...